233 related articles for article (PubMed ID: 36871072)
1. Identification of m6A/m5C/m1A-associated LncRNAs for prognostic assessment and immunotherapy in pancreatic cancer.
Huang Y; Zhang W; Li Q; Wang Z; Yang X
Sci Rep; 2023 Mar; 13(1):3661. PubMed ID: 36871072
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma.
Wu ZY; Shi ZY
Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5868-5883. PubMed ID: 36066162
[TBL] [Abstract][Full Text] [Related]
3. The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma.
Li D; Li K; Zhang W; Yang KW; Mu DA; Jiang GJ; Shi RS; Ke D
Front Immunol; 2022; 13():918140. PubMed ID: 35833147
[TBL] [Abstract][Full Text] [Related]
4. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
Ren M; Fan B; Cao G; Zong R; Feng L; Sun H
BMC Genomics; 2023 Dec; 24(1):776. PubMed ID: 38097948
[TBL] [Abstract][Full Text] [Related]
5. An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma.
Shao D; Li Y; Wu J; Zhang B; Xie S; Zheng X; Jiang Z
Front Genet; 2022; 13():903117. PubMed ID: 35692827
[No Abstract] [Full Text] [Related]
6. The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma.
Li R; Chen H; Li C; Qi Y; Zhao K; Wang J; You C; Huang H
BMC Bioinformatics; 2023 Jul; 24(1):274. PubMed ID: 37403043
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
8. RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer.
Wang Y; Mao Y; Wang C; Jiang X; Tang Q; Wang L; Zhu J; Zhao M
Ann Med; 2023 Dec; 55(1):2190618. PubMed ID: 37042849
[TBL] [Abstract][Full Text] [Related]
9. The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.
Liu T; Sun L; Li ZZ; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
BMC Gastroenterol; 2023 May; 23(1):147. PubMed ID: 37170222
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma.
Yuan H; Liu J; Zhao L; Wu P; Chen G; Chen Q; Shen P; Yang T; Fan S; Xiao B; Jiang K
Front Immunol; 2021; 12():800268. PubMed ID: 34956238
[TBL] [Abstract][Full Text] [Related]
11. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C
BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697
[TBL] [Abstract][Full Text] [Related]
12. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
14. Identification of RNA Methylation-Related lncRNAs Signature for Predicting Hot and Cold Tumors and Prognosis in Colon Cancer.
He R; Man C; Huang J; He L; Wang X; Lang Y; Fan Y
Front Genet; 2022; 13():870945. PubMed ID: 35464855
[TBL] [Abstract][Full Text] [Related]
15. Novel methylation-related long non-coding RNA clinical outcome prediction method: the clinical phenotype and immune infiltration research in low-grade gliomas.
Li Y; Li X; Yu Z
Front Oncol; 2023; 13():1177120. PubMed ID: 37228500
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma.
Li XQ; Yin SQ; Chen L; Tulamaiti A; Xiao SY; Zhang XL; Shi L; Miao XC; Yang Y; Xing X
BMC Cancer; 2024 Jan; 24(1):116. PubMed ID: 38262966
[TBL] [Abstract][Full Text] [Related]
17. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
Liu Y; Wang T; Fang Z; Kong J; Liu J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a new molecular subtyping and prognostic signature with m6A/m5C/m1A/m7G regulatory genes for hepatocellular carcinoma.
Liu T; Wang Y; Li Z; Sun L; Yang K; Chen J; Han X; Qi L; Zhou X; Wang P
Heliyon; 2023 Nov; 9(11):e21285. PubMed ID: 38027812
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Drug Targets Predicted Using Deep Bioinformatic Analysis of m6A-Associated lncRNA-Based Pancreatic Cancer Model Characteristics and Its Tumour Microenvironment.
Cao PW; Liu L; Li ZH; Cao F; Liu FB
Front Genet; 2022; 13():853471. PubMed ID: 35547245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
